Brainomix

Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis 

The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan (HRCT) imaging biomarkers as a co-primary endpoint 20 January 2026 -- Oxford, England and Illinois, US -- Brainomix, a global leader and pioneer of AI-powered imaging tools in lung fibrosis and stroke, today announced...

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke severity, prior to treatment in patients enrolled in Argenica Therapeutic’s Phase II study of neuroprotective ARG-007 Brainomix AI core lab uses regulatory cleared stroke technology, alongside its foundation-model-powered imaging pipeline for clinical trials, to provide robust baseline phenotyping and efficacy...
First Floor, Seacourt Tower West Way Oxford OX2 0JJ

+44 (0) 1865 582730